Epigenotyping in peripheral blood cell DNA and breast cancer risk: A proof of principle study

PLoS ONE

Volumn 3, Issue 7, 2008, Pages

  Widschwendter, Martin ^a   Apostolidou, Sophia ^a   Raum, Elke ^b   Rothenbacher, Dietrich ^b   Fiegl, Heidi ^a   Menon, Usha ^a   Stegmaier, Christa ^c   Jacobs, Ian J ^a   Brenner, Hermann ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c SAARLAND CANCER REGISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MYOD1 PROTEIN; POLYCOMB GROUP PROTEIN; PROTEIN TITF1; PROTEIN ZNF217; TRANSCRIPTION FACTOR PITX2; REPRESSOR PROTEIN;

ADULT; AGE; AGED; ARTICLE; BLOOD; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; FAMILY HISTORY; FEMALE; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; POPULATION BASED CASE CONTROL STUDY; PREDICTION; RISK ASSESSMENT; BREAST TUMOR; CASE CONTROL STUDY; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; MIDDLE AGED; REGRESSION ANALYSIS; RISK FACTOR;

AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DNA; DNA METHYLATION; EPIGENESIS, GENETIC; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; MIDDLE AGED; REGRESSION ANALYSIS; REPRESSOR PROTEINS; RISK FACTORS;

EID: 50549100645     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002656     Document Type: Article

References (36)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics. CA Cancer J Clin 55: 74-108.
2. Decarli A, Calza S, Masala G, Specchia C, Palli D, et al. (2006) Gail model for prediction of absolute risk of invasive breast cancer: independent evaluation in the Florence-European Prospective Investigation Into Cancer and Nutrition cohort. J Natl Cancer Inst 98: 1686-1689.
3. Feinberg AP, Ohlsson R, Henikoff S (2006) The epigenetic progenitor origin of human cancer. Nat Rev Genet 7: 21-33.
4. Gosden RG, Feinberg AP (2007) Genetics and epigenetics - nature's pen-and-pencil set. N Engl J Med 356: 731-733.
5. Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128: 683-692.
6. Widschwendter M, Jones PA (2002) DNA methylation and breast carcinogenesis. Oncogene 21: 5462-5482.
7. Jirtle RL, Skinner MK (2007) Environmental epigenomics and disease susceptibility. Nat Rev Genet 8: 253-262.
8. Anway MD, Cupp AS, Uzumcu M, Skinner MK (2005) Epigenetic transgenerational actions of endocrine disruptors and male fertility. Science 308: 1466-1469.
9. Cui H, Cruz-Correa M, Giardiello FM, Hutcheon DF, Kafonek DR, et al. (2003) Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 299: 1753-1755.
10. Hitchins MP, Wong JJ, Suthers G, Suter CM, Martin DI, et al. (2007) Inheritance of a cancer-associated MLH1 germ-line epimutation. N Engl J Med 356: 697-705.
11. Suter CM, Martin DI, Ward RL (2004) Germline epimutation of MLH1 in individuals with multiple cancers. Nat Genet 36: 497-501.
12. Widschwendter M, Siegmund KD, Muller HM, Fiegl H, Marth C, et al. (2004) Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 64: 3807-3813.
13. Leu YW, Yan PS, Fan M, Jin VX, Liu JC, et al. (2004) Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res 64: 8184-8192.
14. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, et al. (2007) Epigenetic stem cell signature in cancer. Nat Genet 39: 157-158.
15. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, et al. (2007) A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 39: 237-242.
16. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, et al. (2007) Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 39: 232-236.
17. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, et al. (2000) MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 28: E32.
18. Gail MH, Pfeiffer RM (2005) on criteria for evaluating models of absolute risk. Biostatistics 6: 227-239.
19. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, et al. (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447: 1087-1093.
20. Yang J, Mani SA, Donaher JD, Ramaswamy S, Itzykso RA, et al. (2004) Twist, a master regualator of morphogenesis, plays an essential role in tumor metastasis. Cell 117: 927-939.
21. Angrist M, Bolk S, Halushka M, Lapchak PA, Chakravarti A (1996) Germline mutations in glial cell line-derived neurotrophic factor (GDNF) and RET in a Hirschsprung disease patient. Nat Genet 14: 341-344.
22. Shakya R, Jho EH, Kotka P, Wu Z, Kholodilov N, et al. (2005) The role of GDNF in patterning the excretory system. Dev Biol 283: 70-84.
23. Barberi T, Willis LM, Socci ND, Studer L (2005) Derivation of multipotent mesenchymal precursors from human embryonic stem cells. PLoS Med 2: e161.
24. Garcia-Barcelo MM, Lau DK, Ngan ES, Leon TY, Liu TT, et al. (2007) Evaluation of the thyroid transcription factor-1 gene (TITF1) as a Hirschsprung's disease locus. Ann Hum Genet 71: 746-754.
25. De Langhe SP, Carraro G, Tefft D, Li C, Xu X, et al. (2008) Formation and differentiation of multiple mesenchymal lineages during lung development is regulated by beta-catenin signaling. PLoS ONE 3: e1516.
26. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE (2004) Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 96: 1856-1865.
27. Hasenbrink G, Sievernich A, Wildt L, Ludwig J, Lichtenberg-Frate H (2006) Estrogenic effects of natural and synthetic compounds including tibolone assessed in Saccharomyces cerevisiae expressing the human estrogen alpha and beta receptors. FASEB J 20: 1552-1554.
28. Sievernich A, Wildt L, Lichtenberg-Frate H (2004) In vitro bioactivity of 17alpha-estradiol. J Steroid Biochem Mol Biol 92: 455-463.
29. Krig SR, Jin VX, Bieda MC, O'Geen H, Yaswen P, et al. (2007) Identification of genes directly regulated by the oncogene ZNF217 using chromatin immunoprecipitation (ChIP)-chip assays. J Biol Chem 282: 9703-9712.
30. Nonet GH, Stampfer MR, Chin K, Gray JW, Collins CC, et al. (2001) The ZNF217 gene amplified in breast cancers promotes immortalization of human mammary epithelial cells. Cancer Res 61: 1250-1254.
31. Collins C, Rommens JM, Kowbel D, Godfrey T, Tanner M, et al. (1998) Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proc Natl Acad Sci USA 95: 8703-8708.
32. Kallioniemi A, Kallioniemi OP, Piper J, Tanner M, Stokke T, et al. (1994) Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc Natl Acad Sci USA 91: 2156-2160.
33. Terry P, Jain M, Miller AB, Howe GR, Rohan TE (2002) Dietary intake of folic acid and colorectal cancer risk in a cohort of women. Int J Cancer 97: 864-867.
34. Weisenberger DJ, Campan M, Long TI, Kim M, Woods C, et al. (2005) Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res 33: 6823-6826.
35. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, et al. (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 19: 781-791.
36. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, et al. (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38: 787-793.